AstraZeneca's Symbicort ([budesonide + formoterol]) Overview 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Symbicort" report has been added to ResearchAndMarkets.com's offering.

AstraZeneca's Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma.

This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009. In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.

Key Topics Covered:

Product Profiles

Symbicort: Asthma

Symbicort: Chronic obstructive pulmonary disease (COPD)

List of Figures

Figure 57: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 58: Trelegy Ellipta for asthma - SWOT analysis

Figure 3: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 60: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

4 Table 1: Symbicort drug profile

Table 2: Symbicort pivotal trial data in asthma

Table 3: Symbicort late-phase trial data in asthma

Table 4: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 5: Symbicort drug profile

Table 6: Overview of pivotal trial data for Symbicort in COPD

For more information about this report visit https://www.researchandmarkets.com/research/ml8pds/astrazenecas?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs